Alex Saigh
Analyst · Bank of America. Your line is open
Thank you very much, Dean, and thanks for participating in our call. This is Alex again here. Our performance fees for 2021 is basically composed by or derived from two funds, Private Equity Fund III and Private Equity Fund V as you know. On Private Equity Fund III, our main asset there, which is 90% of the remaining net asset value or the NAV of the fund is one listed company which is an imaging diagnostics company. They had called Alliar, you can check that, if you want to, it is a listed company in the Brazilian Stock Exchange B3 and it had a great quarter, it had a great first quarter of 2021 and the results actually did please investors as the stock went up by 25% versus how the stock closed by the end of 2020. So great performance there because this company it is an imaging diagnostic company, but it does -- it did negatively impact -- it got negatively impacted by COVID because the elective surgeries were canceled, with the rebound in the fourth quarter and the first quarter, you can see the results of the company coming back and you can see now the results are great and the stock prices were up. So, we were expecting to see that because, of course, we are a major shareholder of the company and we expect this company to actually continue performing extremely well this year, as we see the vaccination programs in the region, as mentioned, over 110 million people already vaccinated, it's a 500-and-something-million region -- people region, so 20%, and the vaccination programs on a daily basis speeding up. So, as that happens, we see actually then a good second and third quarter for that specific company. In addition to that, as I mentioned in my last question, Dean, with interest rates going up a little bit in Brazil and other regions in Latin America, we have a stabilization or even a strengthening of the currencies in the region, because investors, international -- local, international come back and they want to invest in the local fixed income market in order to find some yield, which is not something hard to find around the world. So, the increase in interest rates actually helps to stabilize the currencies in the region or even strengthen plus we have a record-high increase in commodity prices, as you know, if you look at the data from -- you can see one data to the other data, but approximately a 50% increase in commodity prices from their lows sometime last year and that benefits the region as well because the some of the economies in the region do benefit from high commodity prices, copper in Chile, agribusiness, iron ore in Brazil, oil in Colombia at $70 a barrel, as you know. So all of that push is pushing on one side, on the macro side the rebound in the region, which we look very positively, the commodity prices helping GDP growth that helps the major economies in the region. The interest rates now small hike which actually stabilizes the currencies in the region and in addition actually strengthen the currency in the region since investors come and invest in these currencies in these markets to get some yields. On a micro level Alliar which is the imaging diagnostic company for Fund III performing extremely well with a 25% rebound on its share price this year. So as we look into the year, we're still here in May, we see that sometime this year, we want to divest from the company but I think it was great that we actually waited to see that rebound. And I think we want to wait for the second wave to go through and in now third quarter, fourth quarter to do that divestment in order to actually write all of these positive things that I just mentioned on Alliar stock. But even if we do sell the stock at the current prices, because of a catch-up in country which now we can go offline explaining a little bit that all of the actually resources, most of the resources from the sale of that stock actually goes to pay our performance fees because we have a full catch up on Fund III. So, even if we did sell the stock at this moment, it won't affect much the overall number of performance fees for our Private Equity Fund III. On Private Equity Fund V, no it's not only the returns are just starting as far I'm concerned, now 32% net IRR in US dollars as of the first quarter of this year. But out of the nine companies, seven of them, I think are ready to go to an exit mode, two of them, we filed for an IPO, one of them is another healthcare company, an HMO integrated with hospitals, and the other one that we actually just filed today or yesterday is a network of gyms or fitness centers. So both of them, I think will look into the year and now using again all of the upsides and good news and I see the region announcing over the next quarters now not only IPO, the IPO includes some secondary trade for Fund V, but also during the year, we could do follow-ons and whatever. So as I stand right now, I think I'm pretty positive on Fund III and Fund V, Private Equity Fund III and Private Equity Fund V in generating that performance fee. It might be a case, there are some, I know it's in third quarter and fourth quarter there's now another wave of COVID, or if something strange happens and diverse us from the track that I am describing right now, it has been, as you know, very volatile during the last months. Thank God, the second wave in the region has not been that bad and the vaccination programs are advancing but who knows what can come up, now another variants of the virus and whatever, but given the same temperature and the same pressure here, I'm positive on generating the fees this year. And more so, I'm very positive on FRE, I know that that was not part of your question, but if I can use the answer here to comment on FRE. Marco and I mentioned I think during our call today, how we have been able to deploy more capital in our flagship funds which increases then the fees that we charge and also how we have been able to control expenses extremely in a disciplined manner. So, we see an increase in revenues, we see an increase in FRE above our expectations and we see mid-50% margins, then in the first quarter, we posted 57% FRE margin. So not only, I see -- I'm pretty positive on the FRE side, as I am on the performance fee-related side as well, given where I just sit. Finishing up here, I think when we look into the very short term, which is 2022, I mentioned that, but Marco also mentioned, sorry to be redundant and emphasizing this, but as we do deploy more capital and with these kind of very, very strong performance that we're posting for Private Equity Fund V and Fund VI, Fund VI is 18% [ph] net IRR in US dollars. We are looking to anticipate the fundraising of Private Equity Fund VII, which in our projections was way back in late '22. And looking into having that fundraising happens late this year, beginning of next year. So that also will generate now fees for us to charge in '22, which was not expected not for us at least in our projections. So all of this, I think there is now a group -- a great set and group of good news on the performance fees as well. Hope I answered your question. Long answer here, I'm sorry, but hopefully I was able to answer.